Qualitative or quantitative defects of integrin alpha-7

Qualitative or quantitative defects of integrin alpha-7 refer to a rare congenital myopathy caused by mutations in the ITGA7 gene, which encodes the integrin alpha-7 subunit. Integrin alpha-7 is a key cell-surface receptor that, together with integrin beta-1, mediates the attachment of muscle fibers to the surrounding extracellular matrix (particularly laminin). When this protein is absent, reduced, or dysfunctional, the structural connection between skeletal muscle cells and their basement membrane is compromised, leading to a form of congenital muscular dystrophy. Affected individuals typically present in early life with delayed motor milestones, muscle weakness (particularly proximal), and hypotonia. The condition primarily affects the skeletal muscular system. Some patients may show mild intellectual disability, and the severity of the disease can vary. Serum creatine kinase levels may be mildly to moderately elevated. Muscle biopsy findings may show dystrophic or myopathic changes with reduced or absent integrin alpha-7 expression on immunohistochemistry. This condition is extremely rare, with only a small number of cases reported in the medical literature. There is currently no specific or curative treatment available. Management is supportive and symptomatic, focusing on physical therapy, rehabilitation, orthopedic interventions as needed, and monitoring for potential complications such as contractures or respiratory insufficiency. Genetic counseling is recommended for affected families.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Qualitative or quantitative defects of integrin alpha-7